Comparator: Ribavirin

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Chronic Genotype 1 Hepatitis C Virus InfectionHepatitis C

Phase 2

Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007)

CompletedNCT00704184

Merck Sharp & Dohme LLCHepatitis C

Start: 2008-07-25End: 2010-04-14Updated: 2018-10-09

Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN)

WithdrawnNCT00895882

Merck Sharp & Dohme LLCChronic Genotype 1 Hepatitis C Virus Infection

Start: 2010-11-30End: 2013-01-31Updated: 2015-10-22